Immunome Historical Financial Ratios

IMNM Stock

USD 13.55 0.08 0.59%

Immunome is lately reporting on over 92 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 1.86 or Days Sales Outstanding of 6.02 will help investors to properly organize and evaluate Immunome financial condition quickly.

Quick Ratio Current Ratio

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.

About Immunome Financial Ratios Analysis

ImmunomeFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Immunome investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Immunome financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Immunome history.

Immunome Financial Ratios Chart

At this time, Immunome's Net Debt To EBITDA is very stable compared to the past year. As of the 30th of November 2024, Tangible Book Value Per Share is likely to grow to 6.34, while Operating Cash Flow Per Share is likely to drop (0.40).

Price To Sales Ratio Days Sales Outstanding Ev To Sales Payables Turnover Payout Ratio Debt To Equity

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Immunome stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Immunome sales, a figure that is much harder to manipulate than other Immunome multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Payout Ratio

Payout Ratio is the proportion of Immunome earnings paid out as dividends to shareholders. Payout Ratio is typically expressed as a percentage but can be shown as dividends paid out as a proportion of cash flow. The payout ratio is used to determine the sustainability of Immunome dividend payments. A lower payout ratio is generally preferable to a higher payout ratio, with a ratio greater than 100% indicating Immunome is paying out more in dividends than it makes in net income.

Debt To Equity

A measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets.

Most ratios from Immunome's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Immunome current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.At this time, Immunome's Net Debt To EBITDA is very stable compared to the past year. As of the 30th of November 2024, Tangible Book Value Per Share is likely to grow to 6.34, while Operating Cash Flow Per Share is likely to drop (0.40).

	2021	2022	2023	2024 (projected)
Current Ratio	5.82	3.09	6.63	4.38
Net Debt To EBITDA	2.04	0.55	3.43	3.6

Current Ratio Net Debt To E B I T D A

Immunome fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio
Price To Sales Ratio		-0.41	1.0	-0.55	-0.52	-0.56	-0.86	-0.41	1.0	-0.56	0.42	-0.17	-0.01	0.01	-0.94	1.0	-0.84	0.89	0.75	0.86	0.88	0.37	0.9	0.41	0.85	-0.13
Ptb Ratio	-0.41		-0.41	0.8	0.31	0.69	0.36	1.0	-0.41	0.7	-0.71	0.7	0.52	-0.6	0.31	-0.41	0.77	-0.52	-0.64	-0.3	-0.52	0.51	-0.65	-0.72	-0.42	-0.16
Days Sales Outstanding	1.0	-0.41		-0.55	-0.52	-0.56	-0.86	-0.41	1.0	-0.56	0.42	-0.17	-0.01	0.01	-0.94	1.0	-0.84	0.89	0.75	0.86	0.88	0.37	0.9	0.41	0.85	-0.13
Book Value Per Share	-0.55	0.8	-0.55		0.51	0.99	0.5	0.8	-0.55	0.99	-0.77	0.57	0.8	-0.43	0.47	-0.54	0.76	-0.73	-0.76	-0.43	-0.74	0.36	-0.77	-0.78	-0.71	-0.45
Free Cash Flow Yield	-0.52	0.31	-0.52	0.51		0.58	0.5	0.31	-0.52	0.58	0.12	0.37	0.36	-0.34	0.55	-0.52	0.65	-0.73	-0.17	-0.58	-0.74	-0.31	-0.59	0.12	-0.8	-0.64
Operating Cash Flow Per Share	-0.56	0.69	-0.56	0.99	0.58		0.52	0.69	-0.56	1.0	-0.69	0.51	0.81	-0.37	0.51	-0.56	0.73	-0.76	-0.72	-0.46	-0.77	0.26	-0.77	-0.7	-0.77	-0.52
Capex To Depreciation	-0.86	0.36	-0.86	0.5	0.5	0.52		0.36	-0.86	0.52	-0.34	-0.14	0.0	0.3	0.91	-0.86	0.79	-0.85	-0.65	-0.97	-0.84	-0.55	-0.87	-0.35	-0.8	0.16
Pb Ratio	-0.41	1.0	-0.41	0.8	0.31	0.69	0.36		-0.41	0.7	-0.71	0.7	0.52	-0.6	0.31	-0.41	0.77	-0.52	-0.64	-0.3	-0.52	0.51	-0.65	-0.72	-0.42	-0.16
Ev To Sales	1.0	-0.41	1.0	-0.55	-0.52	-0.56	-0.86	-0.41		-0.56	0.42	-0.17	-0.01	0.01	-0.94	1.0	-0.84	0.89	0.75	0.86	0.88	0.37	0.9	0.41	0.85	-0.13
Free Cash Flow Per Share	-0.56	0.7	-0.56	0.99	0.58	1.0	0.52	0.7	-0.56		-0.7	0.51	0.81	-0.38	0.5	-0.56	0.73	-0.76	-0.72	-0.46	-0.77	0.26	-0.77	-0.7	-0.76	-0.52
Roic	0.42	-0.71	0.42	-0.77	0.12	-0.69	-0.34	-0.71	0.42	-0.7		-0.39	-0.51	0.23	-0.33	0.42	-0.52	0.43	0.88	0.22	0.43	-0.52	0.59	1.0	0.34	-0.1
Inventory Turnover	-0.17	0.7	-0.17	0.57	0.37	0.51	-0.14	0.7	-0.17	0.51	-0.39		0.48	-0.98	0.09	-0.17	0.49	-0.33	-0.38	0.06	-0.34	0.64	-0.34	-0.38	-0.32	-0.39
Net Income Per Share	-0.01	0.52	-0.01	0.8	0.36	0.81	0.0	0.52	-0.01	0.81	-0.51	0.48		-0.45	-0.08	-0.01	0.26	-0.26	-0.3	0.1	-0.28	0.58	-0.26	-0.53	-0.31	-0.78
Days Of Inventory On Hand	0.01	-0.6	0.01	-0.43	-0.34	-0.37	0.3	-0.6	0.01	-0.38	0.23	-0.98	-0.45		0.08	0.01	-0.33	0.16	0.17	-0.22	0.18	-0.66	0.16	0.22	0.17	0.46
Payables Turnover	-0.94	0.31	-0.94	0.47	0.55	0.51	0.91	0.31	-0.94	0.5	-0.33	0.09	-0.08	0.08		-0.94	0.83	-0.93	-0.73	-0.95	-0.92	-0.52	-0.91	-0.31	-0.89	0.18
Capex To Revenue	1.0	-0.41	1.0	-0.54	-0.52	-0.56	-0.86	-0.41	1.0	-0.56	0.42	-0.17	-0.01	0.01	-0.94		-0.84	0.89	0.75	0.86	0.88	0.37	0.9	0.4	0.85	-0.13
Cash Per Share	-0.84	0.77	-0.84	0.76	0.65	0.73	0.79	0.77	-0.84	0.73	-0.52	0.49	0.26	-0.33	0.83	-0.84		-0.92	-0.77	-0.81	-0.92	-0.09	-0.96	-0.52	-0.86	-0.07
Pocfratio	0.89	-0.52	0.89	-0.73	-0.73	-0.76	-0.85	-0.52	0.89	-0.76	0.43	-0.33	-0.26	0.16	-0.93	0.89	-0.92		0.76	0.89	1.0	0.3	0.97	0.42	0.98	0.14
Interest Coverage	0.75	-0.64	0.75	-0.76	-0.17	-0.72	-0.65	-0.64	0.75	-0.72	0.88	-0.38	-0.3	0.17	-0.73	0.75	-0.77	0.76		0.61	0.76	-0.14	0.86	0.86	0.68	-0.19
Capex To Operating Cash Flow	0.86	-0.3	0.86	-0.43	-0.58	-0.46	-0.97	-0.3	0.86	-0.46	0.22	0.06	0.1	-0.22	-0.95	0.86	-0.81	0.89	0.61		0.88	0.62	0.87	0.22	0.85	-0.16
Pfcf Ratio	0.88	-0.52	0.88	-0.74	-0.74	-0.77	-0.84	-0.52	0.88	-0.77	0.43	-0.34	-0.28	0.18	-0.92	0.88	-0.92	1.0	0.76	0.88		0.28	0.97	0.42	0.99	0.17
Days Payables Outstanding	0.37	0.51	0.37	0.36	-0.31	0.26	-0.55	0.51	0.37	0.26	-0.52	0.64	0.58	-0.66	-0.52	0.37	-0.09	0.3	-0.14	0.62	0.28		0.18	-0.53	0.32	-0.25
Income Quality	0.9	-0.65	0.9	-0.77	-0.59	-0.77	-0.87	-0.65	0.9	-0.77	0.59	-0.34	-0.26	0.16	-0.91	0.9	-0.96	0.97	0.86	0.87	0.97	0.18		0.59	0.92	0.01
Roe	0.41	-0.72	0.41	-0.78	0.12	-0.7	-0.35	-0.72	0.41	-0.7	1.0	-0.38	-0.53	0.22	-0.31	0.4	-0.52	0.42	0.86	0.22	0.42	-0.53	0.59		0.34	-0.09
Ev To Operating Cash Flow	0.85	-0.42	0.85	-0.71	-0.8	-0.77	-0.8	-0.42	0.85	-0.76	0.34	-0.32	-0.31	0.17	-0.89	0.85	-0.86	0.98	0.68	0.85	0.99	0.32	0.92	0.34		0.27
Pe Ratio	-0.13	-0.16	-0.13	-0.45	-0.64	-0.52	0.16	-0.16	-0.13	-0.52	-0.1	-0.39	-0.78	0.46	0.18	-0.13	-0.07	0.14	-0.19	-0.16	0.17	-0.25	0.01	-0.09	0.27

Click cells to compare fundamentals

Immunome Account Relationship Matchups

Immunome fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Ptb Ratio	(2.17)	2.37	3.1	1.61	1.77	1.86
Book Value Per Share	(6.2)	4.09	4.18	1.37	6.04	6.34
Operating Cash Flow Per Share	(1.67)	(1.2)	(1.58)	(2.37)	(0.38)	(0.4)
Capex To Depreciation	0.38	0.78	0.1	0.39	1.14	1.2
Pb Ratio	(2.17)	2.37	3.1	1.61	1.77	1.86
Free Cash Flow Per Share	(1.71)	(1.26)	(1.59)	(2.39)	(0.42)	(0.44)
Roic	0.3	(0.28)	(0.52)	(2.25)	(0.91)	(0.96)
Net Income Per Share	(1.84)	(1.69)	(2.12)	(3.09)	(5.38)	(5.65)
Payables Turnover	1.12	0.64	0.25	0.26	6.92	7.27
Cash Per Share	0.44	3.93	4.27	1.68	6.96	7.31
Pocfratio	(8.05)	(8.07)	(8.2)	(0.93)	(28.06)	(26.65)
Interest Coverage	(97.62)	(322.66)	(2.5K)	(7.4K)	(8.5K)	(8.1K)
Capex To Operating Cash Flow	(0.0243)	(0.0483)	(0.004334)	(0.008644)	(0.11)	(0.1)
Pfcf Ratio	(7.86)	(7.69)	(8.17)	(0.93)	(25.28)	(24.02)
Days Payables Outstanding	325.24	573.85	1.5K	1.4K	52.72	50.08
Income Quality	0.92	0.68	0.74	0.78	0.0709	0.0673
Roe	0.3	(0.41)	(0.51)	(2.25)	(0.89)	(0.94)
Ev To Operating Cash Flow	(7.84)	(4.84)	(5.52)	(0.24)	(15.23)	(14.47)
Pe Ratio	(7.32)	(5.72)	(6.11)	(0.71)	(1.99)	(2.09)
Return On Tangible Assets	(2.08)	(0.38)	(0.42)	(1.56)	(0.72)	(0.75)
Ev To Free Cash Flow	(7.66)	(4.62)	(5.5)	(0.23)	(13.73)	(13.04)
Net Debt To E B I T D A	0.2	2.3	2.04	0.55	3.43	3.6
Current Ratio	1.88	14.12	5.82	3.09	6.63	4.38
Tangible Book Value Per Share	(6.2)	4.09	4.18	1.37	6.04	6.34
Graham Number	16.01	12.48	14.12	9.78	27.05	25.75
Shareholders Equity Per Share	(6.2)	4.09	4.18	1.37	6.04	6.34
Capex Per Share	0.0406	0.058	0.006847	0.0205	0.0419	0.069
Graham Net Net	(6.64)	3.64	3.52	1.08	5.53	5.8
Interest Debt Per Share	0.075	0.0644	8.67E-4	4.12E-4	4.74E-4	4.5E-4
Enterprise Value Over E B I T D A	(7.74)	(3.45)	(4.2)	(0.19)	(4.08)	(4.28)
Price Earnings Ratio	(7.32)	(5.72)	(6.11)	(0.71)	(1.99)	(2.09)
Price Book Value Ratio	(2.17)	2.37	3.1	1.61	1.77	1.86

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Immunome is a strong investment it is important to analyze Immunome's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Immunome's future performance. For an informed investment choice regarding Immunome Stock, refer to the following important reports:

How To Invest In Immunome

Details

Is Immunome Stock a good investment?

Details

What is Immunome's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.

You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(7.94)

Revenue Per Share

0.189

Quarterly Revenue Growth

(0.18)

Return On Assets

(0.40)

Return On Equity

(2.76)

The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Immunome Historical Financial Ratios

About Immunome Financial Ratios Analysis

Immunome Financial Ratios Chart

Price To Sales Ratio

Ev To Sales

Payables Turnover

Payout Ratio

Debt To Equity

Immunome fundamentals Correlations

Immunome Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Immunome fundamentals Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Days Sales Outstanding	+ 1.0	Price To Sales Ratio
Ev To Sales	+ 1.0	Price To Sales Ratio
Capex To Revenue	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Ev To Sales	+ 1.0	Days Sales Outstanding
Capex To Revenue	+ 1.0	Days Sales Outstanding

Days Of Inventory On Hand	- 0.98	Inventory Turnover
Capex To Operating Cash Flow	- 0.97	Capex To Depreciation
Income Quality	- 0.96	Cash Per Share
Capex To Operating Cash Flow	- 0.95	Payables Turnover
Capex To Revenue	- 0.94	Payables Turnover
Payables Turnover	- 0.94	Ev To Sales